Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VIRX |
---|---|---|
09:32 ET | 5122 | 0.155 |
09:35 ET | 200 | 0.155 |
09:48 ET | 100 | 0.151 |
09:55 ET | 9800 | 0.1509 |
09:57 ET | 8380 | 0.148 |
10:00 ET | 7833 | 0.1481 |
10:02 ET | 2600 | 0.1484 |
10:06 ET | 100 | 0.1489 |
10:11 ET | 100 | 0.1492 |
10:13 ET | 200 | 0.1494 |
10:15 ET | 4231 | 0.1499 |
10:18 ET | 100 | 0.1514 |
10:20 ET | 17600 | 0.1491 |
10:22 ET | 100 | 0.1491 |
10:24 ET | 100 | 0.1491 |
10:26 ET | 100 | 0.1491 |
10:27 ET | 400 | 0.1502 |
10:33 ET | 226 | 0.1501 |
10:40 ET | 1500 | 0.1501 |
10:49 ET | 7346 | 0.1501 |
10:51 ET | 1055 | 0.1501 |
10:54 ET | 61402 | 0.1431 |
10:56 ET | 4900 | 0.1437 |
10:58 ET | 100 | 0.1427 |
11:00 ET | 4248 | 0.1427 |
11:02 ET | 800 | 0.1439 |
11:03 ET | 7001 | 0.1426 |
11:07 ET | 3800 | 0.1449 |
11:12 ET | 1195 | 0.1455 |
11:16 ET | 5191 | 0.147 |
11:18 ET | 700 | 0.147 |
11:20 ET | 100 | 0.1461 |
11:21 ET | 440 | 0.1461 |
11:25 ET | 100 | 0.1447 |
11:34 ET | 100 | 0.1447 |
11:36 ET | 3302 | 0.1452 |
11:38 ET | 2000 | 0.1452 |
11:39 ET | 200 | 0.1452 |
11:43 ET | 5045 | 0.1452 |
11:45 ET | 25562 | 0.1426 |
11:48 ET | 200 | 0.1427 |
11:50 ET | 100 | 0.1426 |
11:52 ET | 756 | 0.1427 |
11:54 ET | 100 | 0.1426 |
11:57 ET | 200 | 0.1462 |
11:59 ET | 437 | 0.1427 |
12:01 ET | 600 | 0.1426 |
12:03 ET | 100 | 0.1427 |
12:12 ET | 655 | 0.1426 |
12:19 ET | 200 | 0.1426 |
12:21 ET | 200 | 0.1426 |
12:24 ET | 700 | 0.1426 |
12:26 ET | 100 | 0.1426 |
12:28 ET | 100 | 0.1426 |
12:30 ET | 200 | 0.1426 |
12:32 ET | 656 | 0.1427 |
12:33 ET | 1300 | 0.143 |
12:35 ET | 1745 | 0.145 |
12:37 ET | 2735 | 0.148969 |
12:39 ET | 100 | 0.145 |
12:42 ET | 331 | 0.145 |
12:44 ET | 200 | 0.143 |
12:46 ET | 100 | 0.1426 |
12:48 ET | 540 | 0.1494 |
12:53 ET | 500 | 0.1426 |
12:55 ET | 100 | 0.1427 |
01:04 ET | 800 | 0.1494 |
01:06 ET | 500 | 0.1426 |
01:22 ET | 600 | 0.1426 |
01:24 ET | 833 | 0.1426 |
01:26 ET | 100 | 0.143 |
01:29 ET | 100 | 0.1426 |
01:31 ET | 500 | 0.1494 |
01:40 ET | 300 | 0.146049 |
01:45 ET | 745 | 0.145 |
01:47 ET | 2747 | 0.1465 |
01:49 ET | 500 | 0.1455 |
01:51 ET | 111 | 0.1492 |
01:54 ET | 199 | 0.1455 |
01:56 ET | 600 | 0.1475 |
01:58 ET | 100 | 0.1475 |
02:00 ET | 200 | 0.1455 |
02:02 ET | 100 | 0.1494 |
02:03 ET | 610 | 0.1465 |
02:05 ET | 100 | 0.1465 |
02:09 ET | 100 | 0.1465 |
02:14 ET | 863 | 0.1465 |
02:16 ET | 440 | 0.1465 |
02:18 ET | 100 | 0.1465 |
02:21 ET | 100 | 0.147 |
02:25 ET | 600 | 0.1485 |
02:27 ET | 613 | 0.1465 |
02:32 ET | 400 | 0.1468 |
02:34 ET | 100 | 0.1468 |
02:36 ET | 102 | 0.1468 |
02:38 ET | 566 | 0.1468 |
02:39 ET | 701 | 0.1469 |
02:41 ET | 373 | 0.1468 |
02:43 ET | 1549 | 0.1468 |
02:45 ET | 877 | 0.1468 |
02:50 ET | 785 | 0.1468 |
02:52 ET | 200 | 0.1479 |
02:54 ET | 228 | 0.1468 |
02:56 ET | 143 | 0.1468 |
02:57 ET | 859 | 0.1468 |
02:59 ET | 607 | 0.1465 |
03:01 ET | 100 | 0.1465 |
03:03 ET | 100 | 0.1465 |
03:06 ET | 10332 | 0.145 |
03:08 ET | 2175 | 0.145 |
03:10 ET | 447 | 0.145 |
03:12 ET | 339 | 0.145 |
03:14 ET | 492 | 0.145 |
03:15 ET | 411 | 0.145 |
03:17 ET | 355 | 0.145 |
03:19 ET | 498 | 0.145 |
03:21 ET | 200 | 0.145 |
03:24 ET | 6910 | 0.145 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Viracta Therapeutics Inc | 6.3M | -0.1x | --- |
Adial Pharmaceuticals Inc | 6.5M | -0.2x | --- |
GRI Bio Inc | 6.2M | 0.0x | --- |
CNS Pharmaceuticals Inc | 6.2M | 0.0x | --- |
Brainstorm Cell Therapeutics Inc | 6.6M | -0.5x | --- |
Transcode Therapeutics Inc | 6.6M | 0.0x | --- |
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 39.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.70 |
EPS | $-1.10 |
Book Value | $0.47 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.